Publications

5674 Results

PACES trial: Evaluating the effectiveness of eflornithine and sulindac in preventing colon adenomas [Review]

Authors
J Zell;N You;J Boughey
Journal / Conference
Bulletin of the American College of Surgeons, Aug;100(8):70-71
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID26419059
Study Number(s)
S0820

Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – transcriptome expression analysis of the phase III trial SWOG-8814

Authors
K Albain;M Crager;WE Barlow;F Baehner;A Bergamaschi;J Rae;P Ravdin;D Tripathy;G Gralow;R Livingston;CK Osborne;JN Ingle;K Pritchard;NE Davidson;LA Carey;D Cherbavaz;AP Sing;AP Shak;G Hortobagyi;DF Hayes
Journal / Conference
San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abst.# P5-07-01;
Year
2015
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

Successful whole transcriptome analysis of 25-year-old samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies

Authors
D Cherbavaz;D Hayes;K Qu;MR Crager;WE Barlow;A Goddard;EM Beasley;J Jeong;F Collin;M-L Liu;J Rae;P Ravdin;D Tripathy;J Gralow;R Livingston;CK Osborne;JN Ingle;K Pritchard;NE Davidson;LA Carey;AP Sing;F Baehner;G Hortobagyi;S Shak;K Albain
Journal / Conference
San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), poster, abst.# P5-07-01;
Year
2015
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy

Authors
PA Ganz;RS Cecchini;TB Julian;RG Margolese;JP Costantino;L Vallow;K Albain;PW Whitworth;ME Cianfrocca;A Brufsky;HM Gross;G Soori;JO Hopkins;L Fehrenbacher;K Sturtz;TF Wozniak;TE Seay;EP Mamounas;N Wolmark
Journal / Conference
San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), abst. S6-05;
Year
2015
Research Committee(s)
Breast

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140)

Authors
M Chavez MacGregor;W Barlow;L Pusztai;MP Goetz;P Rastogi;P Ganz;E Mamounas;S Paik;H Bandos;J Gralow;D Lew;G Hortobagyi
Journal / Conference
San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), TIPs poster, abst.# OT1-03-11;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S1207

A randomized placebo-controlled phase III trial of yeast derived GM-CSF vs peptide vaccination vs GM-CSF plus peptide vaccination vs placebo in patients with "no evidence of disease" after complete surgical resection of “locally advanced" and/or stage IV melanoma: a trial of the ECOG- ACRIN cancer research group (E4697)

Authors
DH Lawson;S Lee;A Tarhini;T Whiteside;LH Butterfield;KA Margolin;MS Ernstoff;MB Atkins;GI Cohen;JM Kirkwood
Journal / Conference
Journal of Clinical Oncology, Dec 1;33(34):4066-4076
Year
2015
Research Committee(s)
Melanoma
PMID
PMID26351350
PMC
PMC4669592
Study Number(s)
E4697

SWOG 0421: Impact of circulating markers of bone metabolism on overall survival in men with metastatic castration resistant prostate cancer (CRPC)

Authors
PN Lara;M Plets;C Tangen;E Gertz;DI Quinn;I Thompson;M Van Loan
Journal / Conference
European Multidisciplinary Meeting on Urological Cancers (EMUC)(Nov 12-15, 2015, Barcelona, Spain), oral presentation; abst O6
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
S0421

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

Authors
R Walter;M Othus;B Lowenberg;G Ossenkoppele;S Petersdorf;T Pabst;M-C Vekemans;F Appelbaum;H Erba;E Estey
Journal / Conference
Haematologica Oct;100(10):e409-11
Year
2015
Research Committee(s)
Leukemia
PMID
PMID26160876
PMC
PMC4591777
Study Number(s)
S0106

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

Authors
W Sikov;DA Berry;C Perou;B Singh;C Cirrincione;S Tolaney;G Somlo;E Port;R Qamar;K Sturtz;E Mamounas;M Golshan;J Bellon;D Collyar;O Hahn;L Carey;C Hudis;E Winer
Journal / Conference
San Antonio Breast Cancer Symposium 2015 (Dec 8-12, 2015, San Antonio, TX), oral, abst. S2-05;
Year
2015
Research Committee(s)
Breast
Study Number(s)
CTSU/C40603

Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60

Authors
F Ravandi;M Othus;S O'Brien;S Forman;C Ha;J Wong;M Tallman;E Paietta;J Racevskis;G Uy;U Borate;P Kebriaei;L Kingsbury;JP Radich;HM Kantarjian;H Erba;FR Appelbaum
Journal / Conference
Blood 126(23):796; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL),oral presentation;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0805